The future of fungal susceptibility testing

Future Microbiology

Volumn 9, Issue 8, 2014, Pages 947-967

  Posteraro, Brunella ^a   Sanguinetti, Maurizio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

antifungals; CLSI; EUCAST; flow cytometry; isothermal microcalorimetry; MALDI TOF MS; molecular resistance detection; PAO culture; susceptibility testing; X plate technology

Indexed keywords

AGAR; ALUMINUM OXIDE; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CASPOFUNGIN; DEOXYCHOLATE SODIUM; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; FLUORESCENT DYE; ITRACONAZOLE; MICAFUNGIN; POROUS ALUMINUM OXIDE; POSACONAZOLE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN; VORICONAZOLE;

AGAR DIFFUSION; AGAR DILUTION; ANALYTIC METHOD; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ANTIFUNGAL SUSCEPTIBILITY TESTING; ASPERGILLUS; BIOTECHNOLOGY; BROTH DILUTION; CANDIDA; DISK DIFFUSION; EPSILOMETER TEST; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; FUNGAL STRAIN; FUNGUS; FUNGUS CULTURE; FUNGUS GROWTH; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; ISOTHERMAL MICROCALORIMETRY; LABORATORY TEST; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROBIOLOGICAL EXAMINATION; MICROCALORIMETRY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DIAGNOSIS; NONHUMAN; REVIEW; SYO SYSTEM; X PLATE TECHNOLOGY; YEAST CELL; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; PROCEDURES; TRENDS;

ANTIFUNGAL AGENTS; ASPERGILLUS; CANDIDA; DRUG RESISTANCE, FUNGAL; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84908031203     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.14.55     Document Type: Review

References (115)

1. Fera MT, La Camera E, De Sarro A. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev. Anti Infect. Ther. 7(8), 981-998 (2009).
2. Türel O. Newer antifungal agents. Expert Rev. Anti Infect. Ther. 9(3), 325-338 (2011).
3. Rodriguez-Tudela JL, Alcazar-Fuoli L, Cuesta I et al. Clinical relevance of resistance to antifungals. Int. J. Antimicrob. Agents 32(Suppl. 2), S111-S113 (2008).
4. Lass-Flörl C, Perkhofer S, Mayr A. In vitro susceptibility testing in fungi: a global perspective on a variety of methods. Mycoses 53(1), 1-11 (2010).
5. Perkhofer S, Mrazek C, Hartl L, Lass-Flörl C. In vitro susceptibility testing in fungi: what is its role in clinical practice? Curr. Infect. Dis. Rep. 12(6), 401-408 (2010).
6. Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J. Clin. Microbiol. 50(9), 2846-2856 (2012).
7. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am. J. Med. 125(1 Suppl.), S3-S13 (2012).
8. Cordonnier C, Pautas C, Maury S et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin. Infect. Dis. 48(8), 1042-1051 (2009).
9. Cornely OA, Aversa F, Cook P et al. Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy. Eur. J. Haematol. 87(4), 289-301 (2011).
10. Posteraro B, Posteraro P, Sanguinetti M. Update on antifungal resistance and its clinical impact. Curr. Fungal Infect. Rep. 7(3), 224-234 (2013).
11. Patterson TF, Kirkpatrick WR, White M et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 79(4), 250-260 (2000).
12. Alexander BD, Johnson MD, Pfeiffer CD et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 56 (12), 1724-1732 (2013).
13. van der Linden JW, Snelders E, Kampinga GA et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg. Infect. Dis. 17(10), 1846-1854 (2011).
14. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fuconazole-resistant bloodstream isolates of Candida glabrata. J. Clin. Microbiol. 50(4), 1199-1203 (2012).
15. Kanafani ZA, Perfect JR. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin. Infect. Dis. 46(1), 120-128 (2008).
16. Eschenauer GA, Carver PL. The evolving role of antifungal susceptibility testing. Pharmacotherapy 33(5), 465-475 (2013).
17. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35(8), 982-989 (2002).
18. Shields RK, Nguyen MH, Press EG et al. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob. Agents Chemother. 56(9), 4862-4869 (2012).
19. Shields RK, Nguyen MH, Press EG, Updike CL, Clancy CJ. Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and echinocandin resistance. Antimicrob. Agents Chemother. 57(12), 6361-6365 (2013).
20. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard M27-A3 (3rd Edition). Clinical and Laboratory Standards Institute, PA, USA (2008).
21. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi. Approved Standard M38-A2 (2nd Edition). Clinical and Laboratory Standards Institute, PA, USA (2008)
22. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). EUCAST defnitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14(4), 398-405 (2008).
23. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope W. EUCAST technical note on the EUCAST defnitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin. Microbiol. Infect. 18(7), e246-e247 (2012)
24. Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin. Microbiol. Infect. 14 (10), 982-984 (2008).
25. Arikan S. Current status of antifungal susceptibility testing methods. Med. Mycol. 45(7), 569-587 (2007).
26. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Moet GJ, Jones RN. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J. Clin. Microbiol. 48 (5), 1592-1599 (2010).
27. Pfaller MA, Espinel-Ingroff A, Boyken L et al. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fuconazole, posaconazole, and voriconazole by use of epidemiological cutoff values. J. Clin. Microbiol. 49(3), 845-850 (2011).
28. Pfaller M, Boyken L, Hollis R et al. Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus isolates. J. Clin. Microbiol. 49 (3), 1110-1112 (2011).
29. Alastruey-Izquierdo A, Cuenca-Estrella M. EUCAST and CLSI. How to assess in vitro susceptibility and clinical resistance. Curr. Fungal Infect. Rep. 6(3), 229-234 (2012).
30. Clinical and Laboratory Standards Institute. Zone Diameter Interpretative Standards, Corresponding Minimal Inhibitory Concentration (MIC) Interpretative Breakpoints, and Quality Control Limits for Antifungal Disk Diffusion Susceptibility Testing of Yeasts; Informational Supplement. CLSI Document M44-S3 (3rd Edition). Clinical and Laboratory Standards Institute, PA, USA (2009).
31. Clinical and Laboratory Standards Institute. Reference Method for Antifungal Disk Diffusion Testng of Non-Dermatophyte Filamentous Fungi; Approved Guideline. CLSI Document M51-A. Clinical and Laboratory Standards Institute PA USA (2010).
32. Cuenca-Estrella M, Rodriguez-Tudela JL. The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agents in vitro. Expert Rev. Anti Infect. Ther. 8(3), 267-276 (2010).
33. Pfaller MA, Diekema DJ, Andes D et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specifc interpretive criteria. Drug Resist. Updat. 14(3), 164-176 (2011).
34. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. CLSI Subcommittee for Antifungal Susceptibility Testing: wild-type MIC distributions, epidemiological cutoff values and species-specifc clinical breakpoints for fuconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 13(6), 180-195 (2010).
35. Pfaller MA, Andes D, Arendrup MC et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specifc interpretive criteria. Diagn. Microbiol. Infect. Dis. 70(3), 330-343 (2011).
36. Cuenca-Estrella M. Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside. Clin. Microbiol. Infect. 20(Suppl. 6), 54-59 (2014).
37. Lass-Flörl C. In vitro susceptibility testing in Aspergillus species: an update. Future Microbiol. 5(5), 789-799 (2010).
38. Pierce CG, Uppuluri P, Tristan AR et al. A simple and reproducible 96-well plate-based method for the formation of fungal bioflms and its application to antifungal susceptibility testing. Nat. Protoc. 3(9), 1494-1500 (2008).
39. Meletiadis J, te Dorsthorst DT, Verweij PE. Use of turbidimetric growth curves for early determination of antifungal drug resistance of flamentous fungi. J. Clin. Microbiol. 41(10), 4718-4725 (2003).
40. Lass-Flörl C, Perkhofer S, Mayr A. In vitro susceptibility testing in fungi: a global perspective on a variety of methods. Mycoses 53(1), 1-11 (2010).
41. Dannaoui E, Paugam A, Develoux M et al. Comparison of antifungal MICs for yeasts obtained using the EUCAST method in a reference laboratory and the Etest in nine different hospital laboratories. Clin. Microbiol. Infect. 16(7), 863-869 (2010).
42. Arendrup MC, Garcia-Effron G, Lass-Flörl C et al. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob. Agents Chemother. 54(1), 426-439 (2010).
43. Espinel-Ingroff A, Arendrup MC, Pfaller MA et al. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob. Agents Chemother. 57(12), 5836-5842 (2013).
44. Pfaller MA, Messer SA, Diekema DJ, Jones RN, Castanheira M. Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3, 764 clinical isolates of Candida by use of CLSI methods and interpretive criteria. J. Clin. Microbiol. 52(1), 108-114 (2014).
45. Martos AI, Romero A, González MT et al. Evaluation of the Etest method for susceptibility testing of Aspergillus spp. and Fusarium spp. to three echinocandins. Med. Mycol. 48(6), 858-861 (2010).
46. Pinto E, Lago M, Branco L, Vale-Silva LA, Pinheiro MD. Evaluation of Etest performed in Mueller-Hinton agar supplemented with glucose for antifungal susceptibility testing of clinical isolates of flamentous fungi. Mycopathologia 177(3-4), 157-166 (2014).
47. Espinel-Ingroff A, Diekema DJ, Fothergill A et al. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J. Clin. Microbiol. 48(9), 3251-3257 (2010).
48. Espinel-Ingroff A, Cuenca-Estrella M, Fothergill A et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob. Agents Chemother. 55(11), 5150-5154 (2011).
49. Espinel-Ingroff A, Fothergill A, Fuller J, Johnson E, Pelaez T, Turnidge J. Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob. Agents Chemother. 55(6), 2855-2859 (2011).
50. Colozza C, Posteraro B, Santilli S, De Carolis E, Sanguinetti M, Girmenia C. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies. Int. J. Antimicrob. Agents. 39(5), 440-443 (2012).
51. Eschenauer GA, Nguyen MH, Shoham S et al. Real-world experience with echinocandin MICs against Candida species: a multi-center study of hospitals that routinely perform susceptibility testing of bloodstream isolates. Antimicrob. Agents Chemother. 58(4), 1897-1906 (2014).
52. Pfaller MA, Chaturvedi V, Diekema DJ et al. Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values. Diagn. Microbiol. Infect. Dis. 73(4), 365-368 (2012).
53. Arendrup MC, Pfaller MA; Danish Fungaemia Study Group. Caspofungin Etest susceptibility testing of Candida species: risk of misclassifcation of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. Antimicrob. Agents Chemother. 56(7), 3965-3968 (2012).
54. Cuenca-Estrella M, Gomez-Lopez A, Alastruey-Izquierdo A et al. Comparison of the Vitek 2 antifungal susceptibility system with the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution reference methods and with the Sensititre YeastOne and Etest techniques for in vitro detection of antifungal resistance in yeast isolates. J. Clin. Microbiol. 48(5), 1782-1786 (2010).
55. Guinea J, Peláez T, Alcalá L, Bouza E. Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus. Diagn. Microbiol. Infect. Dis. 56(1), 53-55 (2006).
56. Morace G, Drago M, Scaltrito MM et al. In vitro activity (MIC and MFC) of voriconazole, amphotericin B, and itraconazole against 192 flamentous fungi: the GISIA-2 study. J. Chemother. 19 (5), 508-513 (2007).
57. Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the Vitek 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fuconazole against Candida spp. J. Clin. Microbiol. 45(3), 796-802 (2007).
58. Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, fucytosine, and voriconazole against Candida spp. J. Clin. Microbiol. 45(11), 3522-3528 (2007).
59. Posteraro B, Martucci R, La Sorda M et al. Reliability of the Vitek 2 yeast susceptibility test for detection of in vitro resistance to fuconazole and voriconazole in clinical isolates of Candida albicans and Candida glabrata. J. Clin. Microbiol. 47(6), 1927-1930 (2009).
60. Borghi E, Latta R, Sciota R et al. Comparative evaluation of the Vitek 2 yeast susceptibility test and CLSI broth microdilution reference method for testing antifungal susceptibility of invasive fungal isolates in Italy: the GISIA3 study. J. Clin. Microbiol. 48 (9), 3153-3157 (2010).
61. Bourgeois N, Dehandschoewercker L, Bertout S, Bousquet PJ, Rispail P, Lachaud L. Antifungal susceptibility of 205 Candida spp. isolated primarily during invasive candidiasis and comparison of the Vitek 2 system with the CLSI broth microdilution and Etest methods. J. Clin. Microbiol. 48(1), 154-161 (2010).
62. Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fuconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values. Diagn. Microbiol. Infect. Dis. 77(1), 37-40 (2013).
63. Peterson JF, Pfaller MA, Diekema DJ, Rinaldi MG, Riebe KM, Ledeboer NA. Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp. J. Clin. Microbiol. 49 (5), 1765-1771 (2011).
64. Astvad KM, Perlin DS, Johansen HK, Jensen RH, Arendrup MC. Evaluation of caspofungin susceptibility testing by the new Vitek 2 AST-YS06 yeast card using a unique collection of FKS wild-type and hot spot mutant isolates, including the five most common Candida species. Antimicrob. Agents Chemother. 57(1), 177-182 (2013).
65. Wenisch C, Moore CB, Krause R, Presterl E, Pichna P, Denning DW. Antifungal susceptibility testing of fuconazole by fow cytometry correlates with clinical outcome. J. Clin. Microbiol. 39(7), 2458-2462 (2001).
66. Vale-Silva LA, Buchta V. Antifungal susceptibility testing by fow cytometry: is it the future? Mycoses 49(4), 261-273 (2006).
67. Pina-Vaz C, Costa-de-Oliveira S, Rodrigues AG, Espinel-Ingroff A. Comparison of two probes for testing susceptibilities of pathogenic yeasts to voriconazole, itraconazole, and caspofungin by fow cytometry. J. Clin. Microbiol. 43(9), 4674-4679 (2005).
68. Ramani R, Chaturvedi V. Flow cytometry antifungal susceptibility testing of pathogenic yeasts other than Candida albicans and comparison with the NCCLS broth microdilution test. Antimicrob. Agents Chemother. 44(10), 2752-2758 (2000).
69. Chaturvedi V, Ramani R, Pfaller MA. Collaborative study of the NCCLS and fow cytometry methods for antifungal susceptibility testing of Candida albicans. J. Clin. Microbiol. 42(5), 2249-2251 (2004).
70. Pina-Vaz C, Sansonetty F, Rodrigues AG, Costa-Oliveira S, Tavares C, Martinez-de-Oliveira J. Cytometric approach for a rapid evaluation of susceptibility of Candida strains to antifungals. Clin. Microbiol. Infect. 7(11), 609-618 (2001).
71. Rudensky B, Broidie E, Yinnon AM et al. Rapid fow-cytometric susceptibility testing of Candida species. J. Antimicrob. Chemother. 55(1), 106-109 (2005).
72. Mitchell M, Hudspeth M, Wright A. Flow cytometry susceptibility testing for the antifungal caspofungin. J. Clin. Microbiol. 43(6), 2586-2589 (2005).
73. Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann. Pharmacother. 43 (10), 1647-1657 (2009).
74. Bouquet O, Kocsis B, Kilár F, Kustos I. Application of chip-based fow cytometry for amphotericin B and fuconazole susceptibility testing on Candida strains. Methods Mol. Biol. 968, 149-154 (2013).
75. Vale-Silva LA, Pinto P, Lopes V, Ramos H, Pinto E. Comparison of the Etest and a rapid fow cytometry-based method with the reference CLSI broth microdilution protocol M27-A3 for the echinocandin susceptibility testing of Candida spp. Eur. J. Clin. Microbiol. Infect. Dis. 31(6), 941-946 (2012).
76. Lass-Flörl C, Nagl M, Speth C, Ulmer H, Dierich MP, Würzner R. Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining. Antimicrob. Agents Chemother. 45(1), 124-128 (2001).
77. Balajee SA, Marr KA. Conidial viability assay for rapid susceptibility testing of Aspergillus species. J. Clin. Microbiol. 40 (8), 2741-2745 (2002).
78. Ramani R, Gangwar M, Chaturvedi V. Flow cytometry antifungal susceptibility testing of Aspergillus fumigatus and comparison of mode of action of voriconazole vis-à-vis amphotericin B and itraconazole. Antimicrob. Agents Chemother. 47(11), 3627-3629 (2003).
79. Clark AE, Kaleta EJ, Arora A, Wolk DM. Matrix-assisted laser desorption ionization-time of fight mass spectrometry: a fundamental shift in the routine practice of clinical microbiology. Clin. Microbiol. Rev. 26(3), 547-603 (2013).
80. Posteraro B, De Carolis E, Vella A, Sanguinetti M. MALDI-TOF mass spectrometry in the clinical mycology laboratory: identifcation of fungi and beyond. Expert Rev. Proteomics. 10(2), 151-164 (2013).
81. Marinach C, Alanio A, Palous M et al. MALDI-TOF MS-based drug susceptibility testing of pathogens: the example of Candida albicans and fuconazole. Proteomics. 9(20), 4627-4631 (2009).
82. Nagy E, Becker S, Sóki J, Urbán E, Kostrzewa M. Differentiation of division I (cfA-negative) and division II (cfA-positive) Bacteroides fragilis strains by matrix-assisted laser desorption/ionization time-of-fight mass spectrometry. J. Med. Microbiol. 60(Pt 11), 1584-1590 (2011).
83. De Carolis E, Vella A, Florio AR et al. Use of matrix-assisted laser desorption ionization-time of fight mass spectrometry for caspofungin susceptibility testing of Candida and Aspergillus species. J. Clin. Microbiol. 50(7), 2479-2483 (2012).
84. Vella A, De Carolis E, Vaccaro L et al. Rapid antifungal susceptibility testing by matrix-assisted laser desorption ionization-time of fight mass spectrometry analysis. J. Clin. Microbiol. 51(9), 2964-2969 (2013).
85. Sparbier K, Schubert S, Weller U, Boogen C, Kostrzewa M. Matrix-assisted laser desorption ionization-time of fight mass spectrometry-based functional assay for rapid detection of resistance against β-lactam antibiotics. J. Clin. Microbiol. 50(3), 927-937 (2012).
86. Sparbier K, Lange C, Jung J, Wieser A, Schubert S, Kostrzewa M. MALDI biotyper-based rapid resistance detection by stable-isotope labeling. J. Clin. Microbiol. 51(11), 3741-3748 (2013).
87. Lu JJ, Tsai FJ, Ho CM, Liu YC, Chen CJ. Peptide biomarker discovery for identifcation of methicillin-resistant and vancomycin-intermediate Staphylococcus aureus strains by MALDI-TOF. Anal. Chem. 84(13), 5685-5692 (2012).
88. Wybo I, De Bel A, Soetens O et al. Differentiation of cfA-negative and cfA-positive Bacteroides fragilis isolates by matrix-assisted laser desorption ionization-time of fight mass spectrometry. J. Clin. Microbiol. 49 (5), 1961-1964 (2011).
89. Kostrzewa M, Sparbier K, Maier T, Schubert S. MALDI-TOF MS: an upcoming tool for rapid detection of antibiotic resistance in microorganisms. Proteomics Clin. Appl. 7(11-12), 767-778 (2013).
90. Chadwick SG, Schuyler JA, Vermitsky JP, Adelson ME, Mordechai E, Gygax SE. X-Plate technology: a new method for detecting fuconazole resistance in Candida species. J. Med. Microbiol. 62(Pt 5), 720-726 (2013).
91. Pfaller MA, Houston A, Coffmann S. Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata. J. Clin. Microbiol. 34(1), 58-61 (1996).
92. de Vasconcelos AA Jr, Menezes EA, Cunha FA. Chromogenic medium for direct susceptibility testing of Candida spp. isolated from urine. Mycopathologia. 172(2), 125-130 (2011).
93. Kirkpatrick WR, Zimmerman JD, Haikal FP et al. Screening for drug-resistant Candida yeasts with chromogenic agar. Med. Mycol. 48(6), 807-816 (2010).
94. Ingham CJ, van den Ende M, Pijnenburg D, Wever PC, Schneeberger PM. Growth and multiplexed analysis of microorganisms on a subdivided, highly porous, inorganic chip manufactured from anopore. Appl. Environ. Microbiol. 71(12), 8978-8981 (2005).
95. Ingham CJ, Boonstra S, Levels S, de Lange M, Meis JF, Schneeberger PM. Rapid susceptibility testing and microcolony analysis of Candida spp. cultured and imaged on porous aluminum oxide. PLoS ONE 7(3), e33818 (2012).
96. Ingham CJ, Sprenkels A, Bomer J et al. The micro-Petri dish, a million-well growth chip for the culture and high-throughput screening of microorganisms. Proc. Natl Acad. Sci. USA 104(46), 18217-18222 (2007).
97. Ingham CJ, van den Ende M, Wever PC, Schneeberger PM. Rapid antibiotic sensitivity testing and trimethoprim-mediated flamentation of clinical isolates of the Enterobacteriaceae assayed on a novel porous culture support.J. Med. Microbiol. 55(Pt 11), 1511-1519 (2006).
98. Ingham CJ, Ayad AB, Nolsen K, Mulder B. Rapid drug susceptibility testing of mycobacteria by culture on a highly porous ceramic support. Int. J. Tuberc. Lung Dis. 12(6), 645-650 (2008).
99. Ingham CJ, Schneeberger PM. Microcolony imaging of Aspergillus fumigatus treated with echinocandins reveals both fungistatic and fungicidal activities. PLoS ONE 7(4), e35478 (2012).
100. Wadsö I. Isothermal microcalorimety: current problems and prospects. J. Therm. Anal. Calorim. 64, 75-84 (2001).
101. Braissant O, Wirz D, Göpfert B, Daniels AU. Use of isothermal microcalorimetry to monitor microbial activities. FEMS Microbiol. Lett. 303(1), 1-8 (2010).
102. Entenza JM, Bétrisey B, Manuel O et al. Rapid detection of Staphylococcus aureus strains with reduced susceptibility to vancomycin by isothermal microcalorimetry. J. Clin. Microbiol. 52(1), 180-186 (2014).
103. Baldoni D, Hermann H, Frei R, Trampuz A, Steinhuber A. Performance of microcalorimetry for early detection of methicillin resistance in clinical isolates of Staphylococcus aureus. J. Clin. Microbiol. 47 (3), 774-776 (2009).
104. von Ah U, Wirz D, Daniels AU. Isothermal micro calorimetry-a new method for MIC determinations: results for 12 antibiotics and reference strains of E. coli and S. aureus. BMC Microbiol. 9, 106 (2009).
105. Manneck T, Braissant O, Haggenmuller Y, Keiser J. Isothermal microcalorimetry to study drugs against Schistosoma mansoni. J. Clin. Microbiol. 49(4), 1217-1225 (2011).
106. Furustrand Tafn U, Clauss M, Hauser PM, Bille J, Meis JF, Trampuz A. Isothermal microcalorimetry: a novel method for real-time determination of antifungal susceptibility of Aspergillus species. Clin. Microbiol. Infect. 18(7), E241-E245 (2012).
107. Furustrand Tafn U, Meis JF, Trampuz A. Isothermal microcalorimetry for antifungal susceptibility testing of Mucorales, Fusarium spp., and Scedosporium spp. Diagn. Microbiol. Infect. Dis. 73(4), 330-337 (2012).
108. Perlin DS. Antifungal drug resistance: do molecular methods provide a way forward? Curr. Opin. Infect. Dis. 22(6), 568-573 (2009).
109. Perlin DS, Zhao Y. Molecular diagnostic platforms for detecting Aspergillus. Med. Mycol. 47(Suppl. 1), S223-S232 (2009).
110. Garcia-Effron G, Dilger A, Alcazar-Fuoli L, Park S, Mellado E, Perlin DS. Rapid detection of triazole antifungal resistance in Aspergillus fumigatus. J. Clin. Microbiol. 46(4), 1200-1206 (2008).
111. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profling mutations in FKS1. Antimicrob. Agents Chemother. 50(6), 2058-2063 (2006).
112. Zhao Y, Perlin DS. Quantitative detection of Aspergillus spp. by real-time nucleic acid sequence-based amplifcation. Methods Mol. Biol. 968, 83-92 (2013).
113. Zhao Y, Stensvold CR, Perlin DS, Arendrup MC. Azole resistance in Aspergillus fumigatus from bronchoalveolar lavage fuid samples of patients with chronic diseases. J. Antimicrob. Chemother. 68 (7), 1497-1504 (2013).
114. Denning DW, Park S, Lass-Flörl C et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin. Infect. Dis. 52 (9), 1123-1129 (2011).
115. Cantón E, Pemán J, Iñiguez C et al. Epidemiological cutoff values for fuconazole, itraconazole, posaconazole, and voriconazole for six Candida species as determined by the colorimetric Sensititre YeastOne method. J. Clin. Microbiol. 51(8), 2691-2695 (2013).